Zacks Research Has Negative Forecast for BMY Q1 Earnings

Bristol-Myers Squibb (NYSE:BMY) – Research analysts at Zacks Research cut their Q1 2025 earnings per share estimates for Bristol-Myers Squibb in a research report issued to clients and investors on Thursday, February 20th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings per share of $1.55 for the quarter, down from their previous forecast of $1.74. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol-Myers Squibb’s Q2 2025 earnings at $1.63 EPS, Q3 2025 earnings at $1.73 EPS, FY2025 earnings at $6.72 EPS, Q1 2026 earnings at $1.34 EPS, Q2 2026 earnings at $1.47 EPS, FY2026 earnings at $5.90 EPS and FY2027 earnings at $6.14 EPS.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%.

BMY has been the topic of several other research reports. Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $55.00 to $73.00 in a research note on Tuesday, November 12th. Daiwa Capital Markets raised Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research note on Wednesday, November 13th. Citigroup lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a report on Tuesday, January 28th. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and lifted their price target for the company from $63.00 to $70.00 in a report on Monday, December 16th. Finally, Cantor Fitzgerald lifted their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $57.86.

Bristol-Myers Squibb Stock Up 0.6 %

Shares of BMY stock opened at $58.25 on Monday. The company’s fifty day moving average price is $57.05 and its 200-day moving average price is $54.56. The company has a market capitalization of $118.21 billion, a price-to-earnings ratio of -13.18, a PEG ratio of 2.07 and a beta of 0.45. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.10. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Hedge Funds Weigh In On Bristol-Myers Squibb

Hedge funds have recently added to or reduced their stakes in the company. Pinney & Scofield Inc. bought a new position in Bristol-Myers Squibb during the 4th quarter valued at about $25,000. Transce3nd LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $28,000. Reston Wealth Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the third quarter valued at $25,000. Hollencrest Capital Management grew its holdings in shares of Bristol-Myers Squibb by 61.3% in the third quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 187 shares during the last quarter. Finally, Fairway Wealth LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter worth about $28,000. 76.41% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Samit Hirawat purchased 1,823 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares of the company’s stock, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 annualized dividend and a dividend yield of 4.26%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is currently -56.11%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.